Last week's FDA panel nod for Cardiome Pharma Corp.'s intravenous atrial fibrillation/flutter drug vernakalant - lately branded Kynapid - came with the expected provisos, and put the company in strong position as the race to market continues for I.V. and oral versions of AF drugs. (BioWorld Financial Watch)